Claims for Patent: 10,391,075

Summary for Patent: 10,391,075

Title:	Antiviral treatments
Abstract:	The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
Inventor(s):	Babu; Yarlagadda S (Birmingham, AL), Chand; Pooran (Birmingham, AL), Bantia; Shanta (Birmingham, AL), Arnold; Shane (Hoover, AL), Kilpatrick; John Michael (Helena, AL)
Assignee:	BioCryst Pharmaceuticals, Inc. (Durham, NC)
Application Number:	15/714,918
Patent Claims:	1. A method for treating an influenza viral infection in a human comprising administering in a single intravenous administration an effective anti-viral amount of a compound of formula I: ##STR00026## or a pharmaceutically acceptable salt thereof, to the human, wherein the effective anti-viral amount is less than or equal to 600 mg and the influenza viral infection is a type A, type B, H3N2, H1N1, H5N1, avian, or seasonal influenza viral infection. 2. The method of claim 1, wherein the compound of formula I is a compound of formula Ia: ##STR00027## or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the effective anti-viral amount is less than or equal to 500 mg. 4. The method of claim 1, wherein the effective anti-viral amount is less than or equal to 400 mg. 5. The method of claim 1, wherein the effective anti-viral amount is less than or equal to 300 mg. 6. The method of claim 1, wherein the effective anti-viral amount is less than or equal to 200 mg. 7. The method of claim 1, wherein the effective anti-viral amount is less than or equal to 150 mg. 8. The method of claim 1, wherein the effective anti-viral amount is less than or equal to 75 mg. 9. The method of claim 1, wherein the effective anti-viral amount is about 600 mg. 10. The method of claim 1, wherein the effective anti-viral amount is about 300 mg. 11. The method of claim 1, wherein the influenza viral infection is the type A influenza viral infection. 12. The method of claim 1, wherein the influenza viral infection is the type B influenza viral infection. 13. The method of claim 1, wherein the influenza viral infection is the seasonal influenza viral infection. 14. The method of claim 1, further comprising orally administering a neuraminidase inhibitor to the human. 15. The method of claim 14, wherein the neuraminidase inhibitor that is administered orally is oseltamivir carboxylate. 16. The method of claim 14, wherein the neuraminidase inhibitor that is administered orally is a compound of formula I, II, III, or IV: ##STR00028## or a pharmaceutically acceptable salt thereof. 17. The method of claim 14, wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, IIa, IIIa, or IVa: ##STR00029## or a pharmaceutically acceptable salt thereof. 18. The method of claim 14, wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, ##STR00030## or a pharmaceutically acceptable salt thereof. 19. The method of claim 14, wherein the neuraminidase inhibitor that is administered orally is administered for up to 20 days. 20. The method of claim 14, wherein the neuraminidase inhibitor that is administered orally is administered for up to 10 days. 21. The method of claim 14, wherein the neuraminidase inhibitor that is administered orally is administered for up to 5 days.